AM Policy Update: March 15, 2026

Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I

The DEA temporarily placed bromazolam, a benzodiazepine analog, in Schedule I due to abuse potential, restricting its availability and research applications in controlled substance regulations.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I

The DEA placed three synthetic opioids (butonitazene, flunitazene, and metodesnitazene) in Schedule I, establishing their classification as drugs with no accepted medical use and high abuse potential.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

The DEA placed ethylphenidate, a synthetic stimulant, into Schedule I, establishing it as a controlled substance with no accepted medical use, relevant to cannabis medicine’s regulatory framework for scheduling psychoactive compounds.

Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I

The DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, restricting their legal availability, though these synthetic opioids have limited direct relevance to cannabis medicine regulation.

Importer of Controlled-Biopharmaceutical(2024-20085)DEA1425

# Regulatory Summary DEA registration (2024-20085) permits an entity to import controlled biopharmaceuticals, including cannabis-derived medicinal products, for authorized research, manufacturing, or distribution purposes under federal oversight.

Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I

The DEA temporarily placed synthetic opioids N-desethyl isotonitazene and N-piperidinyl etonitazene into Schedule I, restricting their availability; not directly relevant to cannabis medicine regulation.

Schedules of Controlled Substances: Rescheduling of Marijuana

# Regulatory Summary The DEA rescheduled marijuana to a lower controlled substance category, potentially expanding legal medical cannabis research and patient access while maintaining federal restrictions.

Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I

The DEA placed three synthetic opioids (etodesnitazene, N-pyrrolidino etonitazene, and protonitazene) into Schedule I, restricting their availability; this action is minimally relevant to cannabis medicine regulation.

Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I

The DEA placed three synthetic opioids (butonitazene, flunitazene, and metodesnitazene) into Schedule I, restricting their availability and establishing no accepted medical use—relevant to cannabis medicine as a comparative regulatory precedent.

Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I

# Regulatory Summary The DEA placed 2-Methyl AP-237, a synthetic opioid analog, into Schedule I, establishing it as a controlled substance with no accepted medical use—relevant to cannabis medicine policy as part of broader drug scheduling frameworks.

Schedules of Controlled Substances: Placement of 2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine in Schedule I

The DEA placed two synthetic amphetamine derivatives (2,5-dimethoxy-4-iodoamphetamine and 2,5-dimethoxy-4-chloroamphetamine) into Schedule I, establishing they have high abuse potential and no accepted medical use.

Schedules of Controlled Substances: Temporary Placement of MDMB–4en–PINACA, 4F–MDMB–BUTICA, ADB–4en–PINACA, CUMYL–PEGACLONE, 5F–EDMB–PICA, and MMB–FUBICA into Schedule I

The DEA temporarily placed six synthetic cannabinoids into Schedule I, classifying them as controlled substances with no accepted medical use, restricting their availability for cannabis medicine research and clinical applications.

Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I

The DEA placed ethylphenidate, a synthetic stimulant, in Schedule I, establishing it as having no accepted medical use; relevant to cannabis policy as a precedent for scheduling psychoactive substances.

Schedules of Controlled Substances: Placement of Metonitazene in Schedule I

The DEA scheduled metonitazene, a synthetic opioid, as a Schedule I controlled substance, establishing it as having high abuse potential and no accepted medical use, distinct from cannabis medicine regulations.

Schedules of Controlled Substances: Temporary Placement ofEtizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Schedule I

# Regulatory Summary The DEA temporarily placed five benzodiazepine analogs (etizolam, flualprazolam, clonazolam, flubromazolam, diclazepam) in Schedule I, restricting their legal availability and relevance to cannabis medicine research involving controlled substance interactions.

Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224

# Regulatory Summary A biopharmaceutical research company’s DEA application to import controlled substances, including cannabis-derived materials, for medical research and development purposes.

Importer of Controlled-Bright Green(2024-20083)DEA1426

# Regulatory Summary DEA registration 2024-20083 authorizes an importer to legally procure controlled cannabis substances for medical research, manufacturing, or distribution purposes under federal drug enforcement regulations.

Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429

# Regulatory Summary DEA registration 2024-20082 permits Cambridge Isotope Laboratories to import controlled cannabis substances for research and analytical purposes, supporting legitimate scientific investigation of cannabis-derived medicines.

Medicare and Medicaid Programs: Calendar Year 2025 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc.

CMS updates 2025 Medicare/Medicaid payment policies and Part B coverage, potentially affecting reimbursement frameworks for cannabis-derived medical products and practitioner services under federal healthcare programs.

Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare Shared Savings Program Requirements; Medicare Prescription Drug Inflation Rebate Program (CMS-1807-P)

# Regulatory Summary CMS proposed 2025 Medicare Part B payment policies and coverage updates; cannabis remains federally non-covered under Medicare/Medicaid, limiting reimbursement opportunities for cannabis-based medicinal products.